HTR3B

5-hydroxytryptamine receptor 3B · O95264 · HTR3B on Sugi Atlas →

71,363 patent compounds predicted against HTR3B, 48,127 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tropisetron (SCHEMBL18297)	1.00	7/20
Tropisetron (SCHEMBL18299)	1.00	7/20
Tropisetron (SCHEMBL133873)	0.98	7/20
Dolasetron (SCHEMBL42063)	0.72	7/20
Dolasetron (SCHEMBL42064)	0.72	7/20
Dolasetron (SCHEMBL42065)	0.72	7/20
Dolasetron (SCHEMBL41145)	0.65	7/20
Dolasetron (SCHEMBL41146)	0.65	7/20
Mirisetron (SCHEMBL194840)	0.59	7/20
Mirisetron (SCHEMBL194841)	0.59	7/20
Mirisetron (SCHEMBL121861)	0.55	6/20
Mirisetron (SCHEMBL121862)	0.55	6/20
Phenylpiperazine (SCHEMBL24889)	1.00	5/20
Phenylpiperazine (SCHEMBL55125)	1.00	5/20
SCHEMBL166140	1.00	5/20
SCHEMBL232655	0.61	5/20
SCHEMBL59331	0.61	5/20
SCHEMBL164098	0.56	5/20
SCHEMBL221254	0.55	5/20
Noxiptiline (SCHEMBL49824)	0.52	5/20

Clinical trials — most relevant to HTR3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease	PHASE4	NOT_YET_RECRUITING
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms	PHASE3	COMPLETED
Clinical Neurobiology of Serotonin and Addiction	PHASE2/PHASE3	COMPLETED
Vortioxetine for the Treatment of Hoarding Disorder	PHASE3	WITHDRAWN
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY	PHASE1	COMPLETED
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	EARLY_PHASE1	UNKNOWN
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Correlation Between Peri-implantitis and Assumptions of Medications	nan	COMPLETED
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.	nan	COMPLETED
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder	nan	WITHDRAWN
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Vortioxetine for Cancer Patients With Depression: An Observational Study	nan	UNKNOWN
Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain	nan	ENROLLING_BY_INVITATION
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder	nan	COMPLETED
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	nan	UNKNOWN
Intern Health Study	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a HTR3B binder may also engage these)

Protein	Name	Similarity
Q9JJ16	—	0.994	Q9JJ16 →
Q9JHJ5	—	0.988	Q9JHJ5 →
HTR3E	5-hydroxytryptamine receptor 3E (5-HT3-E) (5-	0.974	landscape →
P04760	—	0.971	P04760 →
P13536	—	0.968	P13536 →
P18916	—	0.967	P18916 →
CHRNG	Acetylcholine receptor subunit gamma	0.964	landscape →
HTR3C	5-hydroxytryptamine receptor 3C (5-HT3-C) (5-	0.960	landscape →
P25109	—	0.955	P25109 →
P02713	—	0.955	P02713 →
P04759	—	0.951	P04759 →
P04758	—	0.951	P04758 →
P35563	—	0.949	P35563 →
P09690	—	0.948	P09690 →
CHRND	Acetylcholine receptor subunit delta	0.947	landscape →
CHRNB1	Acetylcholine receptor subunit beta	0.947	landscape →
P02716	—	0.946	P02716 →
P09660	—	0.946	P09660 →
P02715	—	0.945	P02715 →
P23979	—	0.945	P23979 →
P25110	—	0.945	P25110 →
GABRE	Gamma-aminobutyric acid receptor subunit epsi	0.944	landscape →
P20782	—	0.944	P20782 →
HTR3A	5-hydroxytryptamine receptor 3A	0.941	landscape →
P02717	—	0.941	P02717 →
P02714	—	0.939	P02714 →
O70212	—	0.939	O70212 →
P49580	—	0.937	P49580 →
P05376	—	0.936	P05376 →
CHRNE	Acetylcholine receptor subunit epsilon	0.936	landscape →